|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
69,704 |
$95,127,139.92 |
8.11% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
314,456 |
$90,638,797.44 |
7.73% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
2,833,211 |
$84,656,344.68 |
7.22% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
303,318 |
$82,599,557.76 |
7.04% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
545,701 |
$80,185,304.94 |
6.84% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,441,957 |
$46,323,924.29 |
3.95% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
275,488 |
$46,163,524.16 |
3.94% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
50,461 |
$45,561,236.90 |
3.88% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
186,090 |
$45,392,933.70 |
3.87% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
93,774 |
$43,162,296.72 |
3.68% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
522,907 |
$42,935,893.77 |
3.66% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
74,037 |
$40,165,072.50 |
3.42% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
70,127 |
$39,672,246.44 |
3.38% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
323,549 |
$38,182,017.49 |
3.26% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
603,444 |
$38,095,419.72 |
3.25% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
449,113 |
$30,858,554.23 |
2.63% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
128,185 |
$29,139,014.20 |
2.48% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
161,873 |
$19,903,904.08 |
1.70% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
93,110 |
$19,366,880.00 |
1.65% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
27,775 |
$17,636,569.50 |
1.50% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
95,257 |
$15,218,258.32 |
1.30% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
578,322 |
$13,694,664.96 |
1.17% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
236,102 |
$13,250,044.24 |
1.13% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
39,012 |
$12,211,536.24 |
1.04% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
39,920 |
$9,639,083.20 |
0.82% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
57,745 |
$9,046,331.70 |
0.77% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
320,791 |
$6,239,384.95 |
0.53% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
47,176 |
$6,044,189.12 |
0.52% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
62,725 |
$6,058,607.75 |
0.52% |
| Adaptive Biotechnologies Corporation |
ADPT |
00650F109 |
Biotechnology |
224,868 |
$6,033,208.44 |
0.51% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
161,767 |
$5,923,907.54 |
0.51% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
103,214 |
$5,984,347.72 |
0.51% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
19,718 |
$5,895,682.00 |
0.50% |
| Oruka Therapeutics, Inc. |
ORKA |
687604108 |
Biotechnology |
60,499 |
$5,809,113.98 |
0.50% |
| Caris Life Sciences, Inc. |
CAI |
142152107 |
Biotechnology |
219,848 |
$5,722,643.44 |
0.49% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
35,247 |
$5,407,947.21 |
0.46% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
119,253 |
$5,311,528.62 |
0.45% |
| Iovance Biotherapeutics, Inc. |
IOVA |
462260100 |
Biotechnology |
685,931 |
$5,309,105.94 |
0.45% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
89,737 |
$5,210,130.22 |
0.44% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
37,937 |
$5,131,358.62 |
0.44% |
| Tango Therapeutics, Inc. |
TNGX |
87583X109 |
Biotechnology |
245,359 |
$5,120,642.33 |
0.44% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
40,313 |
$4,862,150.93 |
0.41% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
15,604 |
$4,685,101.00 |
0.40% |
| Dianthus Therapeutics, Inc. |
DNTH |
252828108 |
Biotechnology |
53,078 |
$4,406,004.78 |
0.38% |
| Enliven Therapeutics Inc. |
ELVN |
29337E102 |
Biotechnology |
96,805 |
$4,335,895.95 |
0.37% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
193,833 |
$4,117,012.92 |
0.35% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
84,538 |
$4,131,372.06 |
0.35% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
68,017 |
$3,908,256.82 |
0.33% |
| Liquidia Technologies, Inc. |
LQDA |
53635D202 |
Biotechnology |
82,203 |
$3,657,211.47 |
0.31% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Pharmaceuticals |
49,443 |
$3,541,602.09 |
0.30% |
| US Dollar |
$USD |
|
Other |
1,297,806 |
$1,297,805.94 |
0.11% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|